1048 completed, 291 terminated, 244 recruiting, 235 unknown. 1272 Phase 2, 508 Phase 1, 435 Phase 3, 87 Phase 4, 70 Not applicable.
Follow Rituximab: new trials by email Literature Review of Rituximab trials Research Report on Rituximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-12-30 | 2026-11-06 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 3 | Not yet recruiting | AstraZeneca | 1200 | 2026-12-22 | 2026-11-02 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris Rituxan (rituximab), Azathioprine (AZA)' plus corticosteroids - Pemphigus Vulgaris, Rituximab (RTx) | Early Phase 1 | Not yet recruiting | Khyber Teaching Hospital | 92 | 2026-12-02 | 2026-08-18 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 52 | 2026-12-01 | 2026-10-20 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-12-01 | 2026-11-06 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Recruiting | University of Utah | 23 | 2026-11-05 | 2026-11-09 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events Rituximab (RTX) - Immune-Related Adverse Events | Phase 1 | Recruiting | Inge Marie Svane | 25 | 2026-10-15 | 2026-10-20 |
| Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 4 | Recruiting | The First Hospital of Jilin University | 26 | 2026-10-15 | 2026-11-02 |
Showing 20 of 2169. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (427) · Lymphoma (407) · Lymphoma, Non-Hodgkin (345) · Leukemia, Lymphocytic, Chronic, B-Cell (315) · Lymphoma, Follicular (305) · Lymphoma, Mantle-Cell (229) · Lymphoma, B-Cell, Marginal Zone (163) · Leukemia (119) · Lymphoma, B-Cell (114) · Burkitt Lymphoma (112) · Recurrence (101) · Waldenstrom Macroglobulinemia (101) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (90) · Arthritis, Rheumatoid (88) · Hodgkin Disease (60)
M.D. Anderson Cancer Center (139) · Hoffmann-La Roche (117) · National Cancer Institute (NCI) (88) · Memorial Sloan Kettering Cancer Center (36) · Mayo Clinic (31) · Genentech, Inc. (26) · Assistance Publique - Hôpitaux de Paris (24) · Dana-Farber Cancer Institute (24) · Alliance for Clinical Trials in Oncology (23) · Ruijin Hospital (23) · Celgene (20) · Massachusetts General Hospital (20) · City of Hope Medical Center (18) · Institute of Hematology & Blood Diseases Hospital, China (18) · National Institute of Allergy and Infectious Diseases (NIAID) (18)
United States (1151) · China (304) · France (282) · Italy (228) · Germany (212) · United Kingdom (204) · Spain (203) · Canada (164) · Australia (148) · Belgium (130) · Poland (125) · South Korea (118) · Czechia (107) · Netherlands (91) · Sweden (86)
Elias Jabbour (7) · Wyndham H Wilson, M.D. (7) · Corinne Haioun, MD (6) · Craig Moskowitz, MD (6) · Emanuele Zucca, MD (6) · Richard Burt, MD (6)
PMID 39513526, PMID 39319495, PMID 34515338, PMID 35787017, PMID 41671463, PMID 26373676, PMID 40550489, PMID 27282998, PMID 32770353, PMID 34778952, PMID 24265828, PMID 30125215, PMID 30575311, PMID 30770362, PMID 32705923, PMID 35622074, PMID 38620092, PMID 42699559, PMID 11807147, PMID 16551963, PMID 16754935, PMID 17654614, PMID 18050221, PMID 19005182, PMID 20007997, PMID 20032498, PMID 20546023, PMID 20548096, PMID 22127691, PMID 22228634, PMID 22337718, PMID 23293082, PMID 23470153, PMID 23753028, PMID 23834234, PMID 23861248, PMID 24002601, PMID 24224624, PMID 24687837, PMID 24802773, PMID 24916506, PMID 25568347, PMID 26083430, PMID 26132314, PMID 27022122, PMID 27695295, PMID 28342637, PMID 29054815, PMID 29255066, PMID 29358183
2023 (28), 2015 (23), 2009 (19), U10CA031946 (17), U10CA032102 (16), P30CA015704 (14), 2014 (13), 2016 (13), P30CA015083 (13), P30CA033572 (12), U10CA180821 (11), 2008 (10), 2019 (10), P30CA016672 (10), U10CA021115 (10)